EPISODE · Dec 12, 2025 · 7 MIN
#073 $SKYE's Weight Loss Wipeout When Biotech Hype Meets Reality
from SueWallSt · host SueWallSt
Skye Bioscience $SKYE promised a breakthrough obesity drug—but when human trial results dropped, it didn’t even outperform a placebo. The stock plunged 60% in one day, and now executives are accused of cashing out while pumping up investor expectations. This episode of Sue Wall Street breaks down the lawsuit, the science spin, and what it means for biotech investors, traders, and anyone chasing the next pharma moonshot. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
What this episode covers
Skye Bioscience $SKYE promised a breakthrough obesity drug—but when human trial results dropped, it didn’t even outperform a placebo. The stock plunged 60% in one day, and now executives are accused of cashing out while pumping up investor expectations. This episode of Sue Wall Street breaks down the lawsuit, the science spin, and what it means for biotech investors, traders, and anyone chasing the next pharma moonshot. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.
NOW PLAYING
#073 $SKYE's Weight Loss Wipeout When Biotech Hype Meets Reality
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.